期刊文献+

冠状动脉支架内再狭窄的发病机制及其防治进展

下载PDF
导出
出处 《新疆医学》 2003年第4期74-77,共4页 Xinjiang Medical Journal
  • 相关文献

参考文献22

  • 1高明喜.血管紧张素Ⅱ受体拮抗剂治疗充血性心力衰竭的现状与进展[J].医学综述,2002,8(2):83-85. 被引量:6
  • 2Feldman LJ, Mazighi M, et at. Differential expression of matrix metalloproteinases after stent implantation and balloon angioplasty in the hypercholesterolemic rabbit. Circulation. 2001 Jun 26:103(25):3117-22.
  • 3Yu CM,Tipoe GL,et al. Effects of combination of angiotensin - converting enzyme inhibitor and angiotensin receptor antagonist on inflammatory cellular infiltration and myocardial interstitial fibrosis after acute myocardial infarction. J - Am- Coll- Cardiol. 2001 Oct:38(4) : 1207 - 15.
  • 4Mervaala EM, Cheng ZJ, et al. Endothelial dysfunction and xanthine Oxidoreductase activity in rats With human renin and angioteminogen genes. Hypertension. 2001 ,Feb:37(2) :414 - 8.
  • 5Guarda E, Fajuri A, et al. D/D genotype Of the gene for angiotensin converting enzymeas a risk factor for post--stent coronary restenosis Rev---Esp--Cardiol. 1999 Jul; 52(7) : 475--80.
  • 6Hoffman R, Mintz GS, et al.Tissue proliferation within and surrounding palmaz-schatz stents is dependent on the aggressiveness of stent implantation technique. Am - J - cardiol. 1999 Apr: 1S ;83(8) :1170 -4.
  • 7Wentzel JJ; helan DM; et al. Coronary stent implantion changes 3 - D vessel geometry and 3-D shear stress distribution. J - Biomech 2000 Oct;33(10) : 1287- 95.
  • 8Yutani C, Imakita M, et al. Coronary atherosclerosis and interventions: pathological sequences and restenosis. Pathol - Int. 1999 Apt;49(4) :273--90.
  • 9Messerli FH,Weber MA,Brunner, HR. Angiotensin Ⅱ recepter inhibition. Arch Inter Med, 1996,156:1957--65.
  • 10Sironi L, Calvio AM, et al. Effect of valsartan on angiotensin Ⅱ--induced plasminogen activator inhibitor- 1 biosynthesis in arterial smooth muscle cells. Hypertension. 2001 Mar; 37(3) :961--6.

二级参考文献16

  • 1Vernon S.Kaul S.Powers ER.et al.Guidelines for the svaluation and mangement of heart failure[J].Am J Cardiol, 1995,26(5): 1376-1388
  • 2McMurray I.Dargie F.Doctors told fo new beart failure treatment[J].Br Herat K.1993.13[Suppl]:19
  • 3McMurray L.Hart W.National institutes of health date fact sheat congestive heart failure in the United States[J]. Eur Heart J, 1992, 13[Suppl]:350.
  • 4Spinale FG.Iannini JP.Muknerjee R.et al.Angiotensin AT1 receptor inhibition,angiotensin-convertion enzyme inhibiton and combination therapy with developing heart failure:celluar mechanisms of action[J].J Card Fail 1998,4(4):325-332.
  • 5Chen XI.Tummala PE.Black HR.et al.Pharmacological profile of Valsartan hemodyamic effects of Valsartan in rats[l]. Circulation,1998,83(7) :952.959.
  • 6Pool PE.The clinical significance of neurohormonal activation[J]. Clin Ther, 1997,19[Suppl 1] :53-57.
  • 7Pitt B.Segal R.maritines FA.et al.Randomised trial of Losartan versus Captropril in patients over 65 with heart failure[J],Lancet 1997,349(12) :747-752.
  • 8Jorde UP.Ennezat PV.Lisker J.et al.Maximally recommended doses of angiotensin-conveting enzyme(ACE)Inhibitor do not completely prevent ACE-mediated formation of Angiotensin Ⅱ in chronic heart failure[J].Circulation 2000,101 ( 8) : 844-846.
  • 9Yamamoto S.Hayahi N.Kometuim M.et al.Pharmacalogical profile of Valsartan an non-peptide angiotenain Ⅱ type 1 receptor antagonist 5th commication:hemodynamic effects of Valsartan in dog heart failure models[J].Arzneimittelforsch.1997.47(5):630-634.
  • 10Stander GE.Mckinnie JJ.Greenberg SS.et al.ACEI and ARB in the treatment of heart failure caused by left ventricular systolic dysfunction[J].Prog Cardiovasc.1999.41(4):265-300.

共引文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部